Table 1.
Demographics and clinical data of 18 patients with S. arizonae infections in our case series
| Age by years (median, range) | 63.5 (27–81) |
| Male to female ratio | 12 : 6 |
| Underlying diseases (No., %) | |
| Diabetes mellitus | 10 (55.6) |
| Hypothyroidism | 2 (11.1) |
| Peptic ulcer diseases | 8 (44.4) |
| Hepatocellular carcinoma | 4 (22.2) |
| Lung cancer | 3 (16.7) |
| Colon cancer | 1 (5.6) |
| Multiple myeloma | 1 (5.6) |
| Hypertension | 7 (38.9) |
| Liver cirrohosis | 6 (33.3) |
| Hepatitis B | 5 (27.8) |
| Hepatitis C | 2 (11.1) |
| Chronic kidney diseases | 3 (16.7) |
| Systemic lupus erythematosus | 1 (5.6) |
| AIDS | 1 (5.6) |
| Symptoms (No., %) | |
| Fever | 9 (50.0) |
| Abdominal discomfort | 7 (38.9) |
| Dyspnea | 7 (38.9) |
| Laboratory data (No., %) | |
| WBC > 10000/μl | 10 (55.6) |
| CRP > 10 mg/dL | 8/17 (47.1) |
| ALT > 44 U/L | 8/17 (47.1) |
| Creatinine > 1.3 mg/dl | 7/17 (41.2) |
| Site of bacterial isolation (No., %) | |
| Blood | 10 (55.6) |
| Bone | 2 (11.1) |
| Abscess | 2 (11.1) |
| Pleural effusion | 2 (11.1) |
| Sputum | 1 (5.6) |
| Stool | 1 (5.6) |
| Ascites | 1 (5.6) |
| Urine | 1 (5.6) |
| Clinical presentations (No., %) | |
| Lower respiratory tract infection | 4 (22.2) |
| Bone and joint infection | 3 (16.7) |
| Gastrointestinal tract infection | 3 (16.7) |
| Intra-abdominal infection/peritonitis | 3 (16.7) |
| Soft tissue infection | 2 (11.1) |
| Mycotic aneurysm | 2 (11.1) |
| Urinary tract infection | 1 (5.6) |
| Definite antibiotic treatment (No., %) | |
| 3rd generation cephalosporins | 13 (72.2) |
| Fluoroquinolones | 3 (16.7) |
| Piperacillin/tazobactam | 1 (5.6) |
| TMP/SMX | 1 (5.6) |
| Intensive care unit stay (No., %) | 9 (50.0) |
| Length of hospitalization, days (mean ± standard deviation) | 19.7 ± 13.7 |
| In-hospital mortality (No., %) | 1 (5.6) |
AIDS acquired immunodeficiency syndrome, WBC white blood cell, CRP C-reactive protein, ALT alanine aminotransferase, TMP/SM trimethoprim/sulfamethoxazole